Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced a non-brokered private offering in Canada of common shares at US$7.50 per share to certain existing institutional shareholders for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to subscription agreements, customary closing conditions and receipt of required approvals including the Toronto Stock Exchange.
The offering will be made under the listed issuer financing exemption (except Quebec) and the company expects to register any shares in the U.S. under the Securities Act via a prospectus supplement. There is no assurance the offering will complete or the amount raised if completed.
Fennec Pharmaceuticals (NASDAQ:FENC) priced an underwritten public offering of 4,666,667 common shares at $7.50 per share, with gross proceeds expected to be approximately $35,000,000 before discounts and expenses.
The underwriters have a 30‑day option to purchase up to an additional 700,000 shares. The offering is expected to close on November 17, 2025, and net proceeds are planned to repay and redeem indebtedness with any remainder for working capital and general corporate purposes.
Fennec Pharmaceuticals (NASDAQ:FENC) announced on November 13, 2025 a proposed underwritten registered public offering of common shares. The company said it will grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold.
Fennec intends to use net proceeds to repurchase and redeem certain indebtedness, with any remaining proceeds for working capital and general corporate purposes. Piper Sandler and Craig-Hallum are joint book-running managers. The offering will be made under a registration statement declared effective by the SEC and the shares will not be offered in Canada.
Fennec Pharmaceuticals (NASDAQ: FENC) reported Q3 2025 results on November 13, 2025: net product sales $12.5M (≈79% YoY) and the company said it achieved its first positive cash flow from operations, with cash and cash equivalents rising to $21.9M as of September 30, 2025. The company recorded a small loss of $0.6M for the quarter and operating loss of $0.19M. Management highlighted accelerating adoption of PEDMARK across major oncology networks and investigator-led studies in review. Preliminary results from the Japan STS-J01 trial are expected in Q4 2025, with potential pursuit of registration and partnering if data are positive.
Fennec Pharmaceuticals (NASDAQ:FENC) reported strong Q2 2025 financial results, with total net revenues of $9.7 million, representing a 33% increase from Q2 2024. The company's flagship product PEDMARK® showed significant growth in both large community practices and academic centers.
Key highlights include the addition of PEDMARK® to a large national oncology group's formulary for patients under 40, continued expansion of the Fennec HEARS™ patient support program, and successful initial uptake of PEDMARQSI® in the UK and Germany. The company strengthened its patent portfolio with a new U.S. patent providing protection until 2039.
Financial results show operating expenses of $12.4 million and a net loss of $3.2 million for Q2 2025. Cash position stood at $18.7 million as of June 30, 2025. The company expects Japan Clinical Trial (STS-J01) results in H2 2025.
Fennec Pharmaceuticals (NASDAQ: FENC), a commercial stage specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025. The results will be released before U.S. markets open, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
The company will host a live webcast accessible through their website, with a replay available for thirty days following the event. Participants are advised to connect at least 15 minutes early to allow for any necessary software downloads.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 13, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss their financial and business results.
Interested parties can access the webcast through the company's website at www.fennecpharma.com under the Investors & Media section. Participants are advised to connect at least 15 minutes before the call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for 30 days following the event.
Fennec Pharmaceuticals (NASDAQ:FENC) reported strong financial results for Q4 and full-year 2024, with PEDMARK® net product sales reaching $29.6 million for the year, a 40% increase from 2023. Q4 2024 sales were $7.9 million, up 13% from Q3.
The company ended 2024 with $26.6 million in cash and equivalents, strengthened by a $43 million upfront payment from the Norgine transaction. Fennec completed early repayment of $13 million of convertible debt, saving approximately $1.5 million in annual interest payments.
Key developments include PEDMARQSI® commercial launches in the UK and Germany, positive NICE recommendation, and continued momentum in the Adolescent and Young Adult segment. The Japan clinical trial (STS-J01) results are expected in H2 2025. Operating expenses increased year-over-year, with selling and marketing at $18.4 million and G&A at $23.1 million for FY 2024.